EN DE
Watch ENCell Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ENCell Co., Ltd (456070) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of ENCell Co., Ltd stock KRW 1,763, price KRW 4,165, that is 57.7% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

EC ENCell Co., Ltd logo Thin data Nov 9, 2026

ENCell Co., Ltd

456070 · KQ
Very expensive, weak quality

Our calculation puts a fair price 58% below what the stock costs today.

Low debt
Revenue last quarter 26% below a year ago.
Fair value 1,763 KRW · Strongly overvalued
Quality 29/100
Weak Growth (revenue 3y −10.6 %/yr in KRW)
Negative free cash flow
Trails peers (1/8)
Narrow moat 12/100
Thin data
Watch ENCell Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

38,250 KRW 4,165 KRW Fair Value 1,763 KRW Aug 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

26‑month range 4,165 KRW – 38,250 KRW · fair‑value band 1,163 KRW – 2,203 KRW · the 4,165 KRW price screens above the 1,763 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow ENCell Co. in your weekly email

Every Wednesday you see whether ENCell Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease.

Show moreShow less

It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

Stock analysis

ENCell Co., Ltd (456070) currently trades at 4,165 KRW, while our model-based Fair Value estimate is 1,763 KRW, 58% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1,163 KRW (bear) to 2,203 KRW (bull), the price of 4,165 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ENCell Co., Ltd reported revenue of 5.3B KRW in FY2025 versus 3.9B KRW in FY2021, a compound +7.7%/yr. Reported net income was −16.1B KRW in FY2025.

Key figures

Market cap 47.7B KRW (≈ $35.3M) Micro · P/S ratio 12.9 · EPS (TTM) −1,783 KRW · Return on equity −57.7% · Return on assets (EBIT) −21.3% (5-year average) · Operating margin −539% · Revenue (TTM) 4.2B KRW · Revenue growth (YoY) −26.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 79% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −58%, 456070 screens richer than that median.

Fair Value models

Bear 1,163 KRW Fair Value 1,763 KRW Bull 2,203 KRW
Price 4,165 KRW · Downside -57.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,163 KRW 1,763 KRW 2,203 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,163 KRW 1,763 KRW 2,203 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 21
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 37
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−27.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.5% (2021) → −339.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

456070 screens overvalued: fair value 58% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare ENCell Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −57.7% · Below median
Profitability
Return on assets −25.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) −26.3% · Bottom 25%
Balance sheet
Debt / equity 0.23× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.21× · Cheaper than median
P/S (12 months) 11.45× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)89 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 456070
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 456070
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 456070
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 456070
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 456070
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 456070
argenx SE ARGX $927.21 $908.40 −2% vs 456070
CSL Limited CSL A$200.77 A$183.04 −9% vs 456070
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 456070
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 456070

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ENCell Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ENCell Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/456070

Frequently asked questions

Is ENCell Co., Ltd (456070) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1,763 KRW versus a price of 4,165 KRW, about 58% lower (overvalued).
What is the fair value of 456070?
Our model-based fair value for ENCell Co., Ltd is 1,763 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 4,165 KRW.
What is the quality score of 456070?
ENCell Co., Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ENCell Co., Ltd (456070)?
Our model-based price target is the fair value of 1,763 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 1,163 KRW, optimistic scenario 2,203 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ENCell Co., Ltd stock forecast for 2026?
Our models put fair value at 1,763 KRW, about 58% lower versus a price of 4,165 KRW (overvalued). Cautious scenario 1,163 KRW, optimistic scenario 2,203 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ENCell Co., Ltd (456070)?
ENCell Co., Ltd reported trailing-twelve-month revenue of about 4.2B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of ENCell Co., Ltd (456070)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ENCell Co., Ltd it is 1,763 KRW per share (as of Nov 9, 2026), against a price of 4,165 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is ENCell Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 456070 trades above its calculated fair value: price 4,165 KRW, fair value 1,763 KRW, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 456070?
No. The price is what the market pays today (4,165 KRW); the fair value is what the company's own numbers justify (1,763 KRW). For ENCell Co., Ltd the two are 2,402 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ENCell Co., Ltd worth?
The market values ENCell Co., Ltd at about 47.7B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 4,165 KRW; our models calculate a fair value of 1,763 KRW per share.
What do the bullish and bearish scenarios say about 456070?
Our models span a range for ENCell Co., Ltd: cautious scenario 1,163 KRW, base 1,763 KRW, optimistic 2,203 KRW per share (as of Nov 9, 2026, price 4,165 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ENCell Co., Ltd (456070)?
Balance-sheet figures for ENCell Co., Ltd (as of Nov 9, 2026): return on equity −57.7%, debt of 0.23 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 456070 from its 52-week high?
ENCell Co., Ltd trades at 4,165 KRW, about 79% below its 52-week high of 20,150 KRW and at the low of 4,165 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,763 KRW is for.
Which stocks are comparable to ENCell Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ENCell Co., Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 4,165 KRW, calculated fair value 1,763 KRW (−58%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 456070 calculated?
We run ENCell Co., Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,763 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ENCell Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ENCell Co., Ltd (456070)?
The closing price on Nov 6, 2026 was 4,165 KRW. Our model-based fair value is 1,763 KRW, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ENCell Co., Ltd right now?
The price sits above even our optimistic bull case (2,203 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,163 KRW to 2,203 KRW) leaves room in how you read the outcome.

Key figures of ENCell Co., Ltd

How large is the market capitalisation of ENCell Co., Ltd (456070)?
The market capitalisation of ENCell Co., Ltd is 47.7B KRW (≈ $35.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ENCell Co., Ltd (456070)?
The price-to-sales ratio of ENCell Co., Ltd is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ENCell Co., Ltd (456070)?
Earnings per share at ENCell Co., Ltd are −1,783 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of ENCell Co., Ltd (456070)?
The return on equity (ROE) of ENCell Co., Ltd is −57.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ENCell Co., Ltd (456070)?
On an EBIT basis the return on assets of ENCell Co., Ltd is −21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ENCell Co., Ltd (456070)?
The operating margin of ENCell Co., Ltd is −539% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ENCell Co., Ltd (456070)?
Revenue at ENCell Co., Ltd is growing −26.3% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ENCell Co., Ltd (456070) generate?
The free cash flow of ENCell Co., Ltd is −13.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ENCell Co., Ltd in the live analysis

One click puts ENCell Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.